000756.SZ
新华制药
SZSE · Healthcare · C 制造业 · CN
CNY 13.17
−2.95%Aug 31, 2026, 08:48 UTC
Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.
Source:Aug 28, 2026, 08:18 UTC
Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.
Source:Aug 25, 2026, 09:06 UTC
Xinhua Pharmaceutical announced its interim results for the six months ended June 2026, with revenue of RMB 4.358 billion, down 6.06% year-on-year, and net profit of RMB 149 million, down 33.35% year-on-year.
Source:Aug 21, 2026, 08:53 UTC
Xinhua Pharmaceutical announced that it received the Drug Registration Certificate for Dapagliflozin Tablets from the National Medical Products Administration in August 2026, following its application submitted to CDE in March 2025.
Source:Jul 4, 2026, 00:38 UTC
Xinhua Pharmaceutical initiated the Phase I clinical trial of its first-in-class innovative drug LXH-1211 tablets for pulmonary arterial hypertension.
Source: